Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 1 CONFIDENTIALINVESTIGATIONAL NEW DRUG PROTOCOL
GABLOFEN®(baclofen injection )3 MG/ML
PROTOCOL NUMBER CNS -GAB 101US
VERSION 1. 1DATED 13MAY 2013
VERSION 2.0DATED 18 DECEMBER 2014
STUDY TO ASSESS THE SAFETY OF 3 MG/ML GABLOFEN®(BACLOFEN 
INJECTION) DELIVERED BY INTRATHECAL ADMINISTRATION USING THE 
SYNCHROMED®II PROGRAMMABLE INFU SION SYSTEM
SPONSOR:
MALLINCKRODT PHARMAC EUTICALS INC.
675 MCDONNELL BLVD
HAZELWOOD, MO  63042
USA
CONFIDENTIAL
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 2 CONFIDENTIALSUMMARY OF CHANGES FROM VERSION 2.3 TO VERSION 3.0
DATED 18 DECEMBER 2014
This protocol amendment was required to change the sponsor from CNS Therapeut ics, Inc. to 
Mallinckrodt Pharmaceuticals, Inc., the SAE reporting information and contact personnel fro m 
Pacific Link Consult ing to Mallinckrodt, and to assign a new medical mo nitor. These and other 
changes are listed below:
1.  Versi on is changed from v 1.1to v2.0 and protocol re -dated as appropriate. Tit le page, headers 
and footers , and proto col textare revised as appropri ate to reflect the new sponsor .
2.  Secti on 13.1 was changed to provide a new medical mo nitor and medical m onitor contact 
inform ation.
3.  Sec tion 13.2.1 and Table 13-3were changed to provide current Mallinckrodt procedures for 
handling serious adverse events and Mallinckrodt contact informat ion.
4.  Secti on 14. 4(Safet y) was changed for co ding of AEs to include presentation by body system 
and preferred term, rather than just body  system . A sentence indicat ing summarizat ion of lab 
abnorm alities at each time point for each cohort was deleted, since labs are not collected in 
this study  beyond baseline. Summarization o f prior and concomitant medicat ion usage will 
be summarized by the number and percentage of subjects receiving each medicat ion within 
each therapeutic class but not by  dose cohort. A sentence was added to indicate that s afety 
analy ses will  be presented by  age group (pedi atric and adult) and for all subjects. Section 
14.4 updates were made in order to be consistent with the approved statist ical analysis plan. 
5.  Minor edits were made to correct grammar and spelling errors.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 3 CONFIDENTIALTABLE OF CONTENTS
LIST OF ABBREVIATIONS ......................................................................................................6
LIST OF IN-TEXT TABLES ......................................................................................................8
LIST OF APPENDICES .............................................................................................................8
PROTOCOL SYNOPSIS (page 1 of 3) ..................................................................................... 11
1.0 INTRODUCTION .......................................................................................................... 14
1.1 Background ................................................................................................................. 14
1.2 Nonclinical Assessments ............................................................................................. 16
1.2.1 Pharmaco logy...................................................................................................... 16
1.2.2 Toxicology ........................................................................................................... 17
1.3 Clinical Experience ..................................................................................................... 17
1.4 Study  Rati onale ........................................................................................................... 17
2.0 PURPOSE AND STUDY OBJECTIVES ....................................................................... 18
2.1 Purpose ....................................................................................................................... 18
2.2 Study  Object ives......................................................................................................... 18
2.2.1 Primary Object ive................................................................................................ 18
2.2.2 Secondary  Object ives........................................................................................... 18
3.0 STUDY DESIGN ........................................................................................................... 18
3.1 Descript ion of Tri al Design ......................................................................................... 18
3.2 Study  Endpo ints.......................................................................................................... 19
3.2.1 Primary Endpo int.................................................................................................19
3.2.2 Secondary  Endpo ints............................................................................................ 19
3.3 Diagnosis of an Inflammatory  Granul oma................................................................... 19
3.3.1 Treatment of an Inflammatory  Granulo ma........................................................... 20
3.4 Measures to Minimize Bias ......................................................................................... 21
3.4.1 Blinding ............................................................................................................... 21
3.4.2 Assignme nt to Study  Drug ................................................................................... 21
3.5 Study  Drugs ................................................................................................................ 21
3.5.1 Rationale for Doses and Dosing Regimen ............................................................ 21
3.5.2 Dosages and Dosing Regimen .............................................................................. 21
3.5.3 Dose Modificat ions.............................................................................................. 22
3.5.4 Dose Interruption .................................................................................................22
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 4 CONFIDENTIAL3.5.5 Pump or Catheter Repl acements ........................................................................... 22
3.6 Concomitant Medications ............................................................................................ 23
3.6.1 Prior and Concomi tant Medicat ions..................................................................... 23
3.6.2 Prohibited Conco mitant Medi cations................................................................... 23
3.7 Durati on of  Therapy .................................................................................................... 23
3.8 Procedures for Monitoring Subject Compliance .......................................................... 23
4.0 STUDY POPULATION .................................................................................................23
4.1 Inclusio n Cri teria........................................................................................................ 24
4.2 Exclusio n Cri teria....................................................................................................... 24
5.0 SAFETY ASSESSMENTS ............................................................................................. 24
5.1 Collection of Adverse Events Data .............................................................................. 24
5.2 Physical Examinat ions and Medical History ................................................................ 25
5.2.1 Com plete Physical Examinat ion........................................................................... 25
5.2.2 Targeted Phy sical Examinati on............................................................................ 25
5.2.3 Medical History ................................................................................................... 25
5.3 Vital Signs .................................................................................................................. 26
5.4 Docum entati on of  Conco mitant Medi cations............................................................... 26
6.0 PHARMACOKINETICS ................................................................................................ 26
7.0 PHAR MACODYNAMICS ............................................................................................. 26
8.0 EFFICACY .................................................................................................................... 26
9.0 STUDY VISITS ............................................................................................................. 27
9.1 Screening .................................................................................................................... 27
9.2 Baseline Evaluat ions................................................................................................... 27
9.3 Interim Study  Visi ts.................................................................................................... 27
9.4 Final Visit ................................................................................................................... 28
10.0 PREMATURE DISCONTINUATION FROM STUDY .................................................. 28
11.0 PREMATURE DISCONTINUATION FROM STUDY DRUG ...................................... 28
12.0 PRODUCT SPECIFICATIONS ..................................................................................... 29
12.1 Descript ion.............................................................................................................. 29
12.2 Form ulation, Packaging, and Labeling ..................................................................... 29
12.3 Receipt, Storage and Stabilit y of Gabl ofen.............................................................. 29
12.4 Preparati on and Administration of Study  Drug ........................................................ 30
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 5 CONFIDENTIAL12.5 Ordering and Distribution of Study  Drug .................................................................30
12.6 Accountabilit y of Study  Drugs ................................................................................. 30
13.0 SAFETY MONITORING AND ADVERSE EVENTS ................................................... 30
13.1 Adverse Events ........................................................................................................ 30
13.2 Serious Adverse Events ........................................................................................... 32
13.2.1 Reporting Requirements for Serious Adverse Events ........................................... 33
13.2.2 Recording of Serious Adverse Events .................................................................. 34
14.0 STATISTICAL CONSIDERATIONS ............................................................................ 35
14.1 Sample Si ze Determinat ion...................................................................................... 35
14.2 Analysis Data Sets ................................................................................................... 35
14.3 Data Analyses .......................................................................................................... 35
14.4 Safety...................................................................................................................... 35
14.5 Preliminary Efficacy ................................................................................................ 36
15.0 DAT ACOLLECTION, STUDY MONITORING, AND DATA DISCLOSURE ............. 36
15.1 Data Collect ion and Reporting ................................................................................. 36
15.2 Study  Moni toring .................................................................................................... 36
15.3 Data Di sclosure and Subject Confident iality............................................................ 36
16.0 PROTECTION OF HUMAN SUBJECTS ...................................................................... 37
16.1 Declaration of Helsinki ............................................................................................ 37
16.2 Institutional Review Board/Ethi cs Co mmittee ......................................................... 37
17.0 REFERENCE LIST ........................................................................................................ 38
18.0 SPONSOR SIGNATURE ............................................................................................... 42
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 6 CONFIDENTIALLIST OF ABBREVIATION S
ABBREVIATION DEFINITION
AE Adverse event
CFR Code of Federal Regulations
cGMP Current Good Manufacturing Practices
CSF Cerebral Spinal F luid
CNS Central nervous system
CRF Case report form
CRU Clinical research unit
CTCAE Common Terminology Criteria for Adverse Events (v. 4.03)
EC Ethics Committee
FDA Food and Drug Administration
g Gram
GABA Gamma -aminobutyric acid
GCP Good Clinical Practice(s)
ICF Infor med Consent Form
ICH International Conference on Harmonization
IRB Institutional Review Board
IT Intrathecal Injection
ITT Intent -To-Treat
IP Investigational Product
kg Kilogram
L Liter
MedDRA Medical Dictionary for Regulatory Activities
mcg Microgram
MFD Maximum Feasible Dose
mg Milligram
mL Milliliter
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 7 CONFIDENTIALABBREVIATION DEFINITION
MRI Magnetic Resonance I maging 
NCI National Cancer Institute
NDA New Drug Application
PI Principal Investigator
SAE Serious Adverse Event 
U.S. United States (of America)
USP United States Pharmacopeia
WHOD D World Health Organization Drug Dictionary
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 8 CONFIDENTIALLIST OF IN -TEXT TABLES
Table 13-1:    Severi ty Assessment Termino logy for Reporting Adverse Events (CTCAE v 4.03) .
......................................................................................................................... 32
Table 13–2 Reporting Requirements for Adverse Events ........................................................ 34
Table 13–3Contact Informat ion for SAE Reporting ............................................................... 34
LIST OF A PPENDICES
Appendix A.  Schedule of Study  Procedures ............................................................................. 39
Appendix B.  National  Cancer Inst itute Commo n Termino logy Cri teria for Adverse Events ......41
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 9 CONFIDENTIALINVESTIGATOR STATEMENT
I have read and understand the protocol and agree to impl ement the study  in accordance wit h the 
procedures set forth in the protocol and in accordance wit h the Sponsor's guidelines, all 
applicable government regulat ions, and the International Conference on Harmoniz ation Good 
Clinical Practice Guidelines E6 ( ICH- GCP , 1996 ).
I will maintain accurate source documents from which data are transcribed onto case report 
forms and accurate drug accountabilit y records that show the receipt and disposit ion of all study  
drugs.
I will provide adequate protocol training to my associates, colleagues, and emplo yees assist ing in 
the conduct of the study . 
I will obtain Inst itutional Review Board/Ethi cs Committee (IRB/EC) approval of the protocol 
and Informed Consent Form prior to enrollment of subjects in th e study . I understand that any  
modificati ons to the protocol  made during the course of the study  must first be approved by  the 
IRB/EC prior to implementation except when such modificat ion is made to rem ove an immediate 
hazard to the subject.
I will ensure that a fully  executed IRB -approved Informed Consent Form is obtained fro m each 
subject pri or to init iation of any study  procedures. 
I will report ( within 24 hours) any  serious adverse event, regardl ess of rel ationship to study  drug, 
or pregnancy that occu rs during the course of the study , in accordance with the procedures 
described in Secti on13.2 of the protocol . I will  notify the Sponsor if I beco me aware that a 
partner of a study  subject becom espregnant while the subject was receiving this study  drug.
I will submit all protocol inclusio n/exclusio n violations to the m edical mo nitor for approval  prior 
to enrollment of the subject in the study .
I will allow the Sponsor, Mallinckrodt Pharmaceuticals , Inc. and i ts agents, as well as the United 
States (U.S.) Food and Drug Administration (FDA) and other regulatory  agencies to inspect 
study  facilities and pertinent records at reasonable times and in a reasonable manner, ensuring 
subject confident iality. If I am  notified that this study  is to be inspected by  a regulatory  agency, I 
will notify  the Sponsor as soon as possible thereafter (no later than 1 week).
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 10 CONFIDENTIALThe contents of this protocol may be disclosed to study  personnel under y our supervisio n and to 
your IRB/EC. The contents of this protocol may  not be di sclosed to any  other parti es (unless 
such di sclosure is requi red by government regulat ions or laws) with out the pri or wri tten approval  
of Mallinckrodt Pharmaceut icals,Inc.
__________________________________________ _______________________
Invest igator’s Signature Date
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 11 CONFIDENTIALPROTOCOL SYNOPSIS (PAGE 1 OF 3 )
Study Title Study to Assess the Safety of 3 mg/mL Gablofen®(baclofen injection ) Delivered by Intrathecal 
Administration Using the SynchroMed®II Programmable Infusion System (CNS -GAB 101US)
Phase IIIb (Open -label Safety)
Study Drug Gablofen®(baclofen injection )
Objectives Primary  objective: 
The primary objective of this safety and post -approval surveillance study is to obtain data on 
the rate of inflammatory granulomas in patients given Gablofen®(baclofen injection) 3mg/mL 
by the intrathecal route of administration .
Secondary objectives:
Toevaluate the overall safety data on 3 mg/mL Gablofen®(baclofen injection) given by the 
intrathecal route of administration.
Study Design This is a prospective twelve -month Phase IIIb clinical safety trial followed by a 2-year, Phase IV 
study that will be conducted at 10 to 15 clinical trial sites that are experienced with the use of 
intrathecal baclofen.  All patients will be entered after signing an IRB approved informed consent. 
Patients will be followed for the duration of their treatment with Gablof en®(baclofen injection)
3mg/m Lusing the SynchroMed®II Programmable Pump or until the study is terminated.  Patients 
will be evaluated for clinical complications associated with the use of intrathecal baclofen that are 
considered signs and symptoms of a n inflammatory granuloma, specifically new radicular pain at 
the level of the catheter tip, and /orspinal cord compression.  Reports will be requested from the 
investigator at every clinical visit for the first 12 months for each pa tient enrolled and then every 
6months thereafter. If there are any signs or symptoms identified which may indicate an 
inflammatory granuloma formation, an MRI scan with and without infusion will be performed 
(with consent of the patient) to evaluate the potential presence of an inflammatory granuloma. 
Events that may be related to an inflammatory granuloma will be classified as adefinite 
granu loma, possible granuloma, other catheter related problem (confirmed not caused by a 
granuloma) ,or other clinical sequelae caused by the underlying disease or other infusion system
related event. An interim analysis will be conducted when 100 subjects on the 3 mg/mL 
concentration of Gablofen®(baclofen injection) reach 9 months of treatment.  Additionally, a 
safety update will be provided to the FDA after the first cohort of 100 patients reach 12 months.   
Thereafter, annual reports to the NDA will be gene rated and provided to the FDA as part of this 
3-year progr am.
Sample Size Up to 150 subjects enrolled (100 completers at 12 -months)
Study 
PopulationMale or female subjects 4years of age or older with severe spasticity and who are being treated 
with intrathecal baclofen.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 12 CONFIDENTIALPROTOCOL SYNOPSIS (P AGE 2 OF 3 )
Main Inclusion 
Criteria1. 4 years of age or older
2.Subjects must be clinically diagnosed with severe spasticity and be receiving intrathecal 
baclofen
3.Subjects must have a SynchroMed®II Pump already implanted
4.Current treatment with intrathecal baclofen should be at the 2 mg/mL concentration
5.Life expectancy 12months
6.Signed written informed consent
7.Ability and willingness to comply with the study protocol for the duration of the study and 
with follow -up procedures
Main Exclusion 
Criteria1.Histor y or presence of malignancy, with the exception of adequately treated localized skin 
cancer (basal cell or squamous cell carcinoma) or carcinoma in -situ of the cervix, which is 
allowed
2.Histor y of any  allergic reaction to baclofen
3.Histor y of inflammatory granulomas with an intrathecal infusion pump
4.Any previous history of neuroleptic malignant syndrome or malignant hyperthermia
5.As a result of medical review and physical examination, the I nvestigator considers the 
subject unfit for the study
Dosage and 
Administration 
of Study DrugSubjects will be on a stable regimen of intrathecal baclofen at a concentration of 2 mg/mL.  
After qualification, the remaining baclofen in the SynchroMed®II Pump will be removed and 
the pump will be loaded with 3 mg/mL Gablofen®as per no rmal filling requirements for a 
SynchroMed®II Pump.  Patients will be monitored by the physician and examined at least every 
6months for the 3-year duration of the study for any indications of complications with the 
device or clinical signs and symptoms of concern.  More frequent visits to the investigating 
physician may  be necessary  for pump refills depending on the daily  dose of baclofen .The total 
daily  dose in this trial will not exceed 2000 mcg /day.A safety evaluation and adverse event 
reports will be requested from the investigator at ever y clinical visit for the first 12 months for 
each patient enrolled and then ever y 6 mo nths thereafter based upon a pre -defined schedule of 
events.
Safety Analysis Subjects will be assessed throughout the study for adverse events and potential clinical signs and 
symptoms of an inflammatory granuloma.  Safety will be assessed through collection of AEs and 
SAEs during the co nduct of the trial.  At each visit, the subject will be queried for any AEs that 
differ from their baseline condition at the time of enrollment into the trial. 
The use of intrathecal opioids has been associated in rare case swith an inflammatory granuloma
at the catheter tip that can result in serious neurological impairment, including paralysis.  While 
these events have not been reported with commercial baclofen that has been unaltered by 
pharmacy compounding, the potential for an inflammatory granuloma with higher 
concentrations of baclofen has not been assessed.  In this study, t he potential for an 
inflammatory granuloma will be assessed at each visit to the investigator.  
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 13 CONFIDENTIALPROTOCOL SYNOPSIS (P AGE 3 OF 3 )
Safety Analysis
(Cont.)Clinical signs and symptoms that may indicate an inflammator y granuloma include:
oa sudden decrease in therapeutic response requiring increased daily doses that is not 
attributed to other assignable causes (e.g. mechanical failures, catheter movement 
or catheter blockages)
ounexplained pain at the dermatomal level of the catheter tip
ounexplained neurological deficit or dysfunction that could be due to compression of 
the spinal cord at the level of a catheter tip
For the purpose of this study, definite inflammatory granuloma is an intramural extra -
medullary m ass at the catheter tip that is confirmed by an infusion MRI . If only clinical signs 
are detected, but the inflammatory granuloma or mass cannot be verified by MRI, and no other 
cause can be determi ned, the event will be classified as a possible inflammatory granuloma .   
If in the opinion of the investigator there is a reasonable probability that the subject may be 
experiencing an inflammatory granuloma, an MRI without and with infusion of a contrast agent 
will be requested.  All MRIs will be assessed by a single central independent radiologist who 
will be blinded to the patient ’s history .  
During the trial, all SAEs reported to the investigator shall be reporte d to the Mallinckrodt 
Pharmacovigilance department within 24 hours of the event being reported to the investigator.  
The investigator will be asked to provide details of the SAE, an assessment of severity of the 
event and an opinion as to relatedness to st udy medication or to o thercauses.
Safety data from the study will be analyzed by the nature, frequency, and severity of drug 
related serious adverse events for all subjects including a t baseline, within study, and the end of 
study. Demographic informatio n will be presented for each subject and summarized. 
Treatment -emergent adverse events and relevant laboratory results will be summarized. Events 
of inflammatory granuloma’s will be described both as part of the descriptive statistics, and 
each event will include a full narrative assessment including MRI reports ,clinical interventions 
and outcome.
Data will be presented as summary statistics. The intent -to-treat (ITT) population includes all 
patients who were deemed eligible, have signed the informed -cons ent form (ICF) and treated 
with 3 mg/m Lbaclofen. The evaluable (or “per protocol”) population is the subset of ITT 
patients who were deemed eligible, signed the ICF, have been clinically evaluated for 
inflammatory granuloma formation through a physical e xamination and evaluation of the 
investigator. The incidence of definite inflammatory granulomas, possible granulomas, and 
other catheter related events will be summarized in annual reports for 3 years.
Efficacy 
AnalysisThere is no efficacy measure in this open -label clinical trial.  However, the dose of baclofen
intrathecal will be monitored during the trial. 
Study Duration It is planned that each subject will participate in the study for a minimum of 12 months with an 
extension for up to 24 addition al months permitted at the discre tionof the patient and attending 
physician. Overall duration of the study will be approximately 48 months, depending on the 
rate of enrollment and number of subjects enrolled.
Study Centers Up to fifteen (15) investigative sites will participate in the study.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 14 CONFIDENTIAL1.0 INTRODUCTION
1.1 Background
Baclofen (Gabl ofen®) is a derivat ive o f gamma -amino butyric acid (GABA) and is an agonist for 
the GABA Breceptors (Mezler et al.,2001 ; Dzitoyeva et al .,2003 ).  It is primarily used to treat 
spast icity and has been a primary treatment for this indicat ion by both oral  and intrathecal routes 
of administrati on.  Baclofen’s beneficial effects in spast icityresul t from actions at the spinal 
level .  Bacl ofen does not seem to significant lyinduce tol erance and maintains itsanti-spasm odic 
effect over many  years.  However, if the underlying disease that is the source of the spast icity 
continues to progress, the dose of baclo fen needed to manage the spast ic symptoms may increase 
over time.
Baclofen USP
Gablo fen® (baclofeninject ion) is indicated for use in the management of severe spast icity in 
adult and pedi atric patients age 4 y ears and above. Gablo fen®(baclo fen injection) is current ly 
approved only for us e in the Medtroni c SynchroMed®IIProgrammable Pump or other pumps 
labeled f or intrathecal  administrati on of  Gabl ofen®(baclo fen inject ion).  The pump is refilled 
with Gabl ofen®(baclo fen injection) using an appropri ate refill kit and according to the pump 
manufacturer’s instructions.  Gablo fen®(bacl ofen inject ion) or other baclo fen products are not 
permitted by  labeling to be compounded wit h other medicat ions for the purpose of intrathecal 
administration.
After confirmat ion of the efficacy of Gablo fen®(bacl ofen inject ion) by intrathecal inject ion, an 
infusio n pump may be im planted.  The dose may  be adj usted by  intrathecal inject ion unt il the 
desired clinical  effect i s obtained.  After implantation of a SynchroMed®IIpump, the dose 
titration of  Gabl ofen®(bacl ofen inject ion) may be adjusted to obtain the optimal clinical eff ect.
Over time, the dose of Gablo fen®(baclofen inject ion) may be increased by up to 20% each time 
the pump is refilled.  Sudden changes in dose may indicate a catheter complicat ion and shoul d be 
carefully  eval uated and correcti ve acti ons taken as appropriate.  At the higher doses, the 
frequency  of pum p refills c an beco me a burden on the patient and medical system.  Thus, a 
higher concentration formulat ion of Gablo fen®(bacl ofen injecti on)is needed to help reduce the 
number of pump refills and improve pat ient qualit y of life.

Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 15 CONFIDENTIALThe purpose of this study  is to eval uate the safet y of a higher concentration, 3 mg/mL o f 
Gablo fen®(bacl ofen inject ion).  
The benefit and risks of intrathecal ( IT)baclo fen are well understood from many years of clinical 
experience andpeer-reviewed publicat ions.Medtroni c has conducted a large publicly  available 
post-approval surveillance study  for the SynchroMed®II Programmable Pump that also includes 
surveillance of various drug products delivered by IT administration.  This study  followed 4,384 
patients wi th implanted SynchroMed®II Programmable Pump drug delivery  systems at fift y (50) 
centers, wi th 3,101 pati ents receiving various other IT medications f or pain and 1,283 patients 
receiving baclo fen for spasticit y.  Included in Medtronic’s study  was a careful e xaminat ion of 
inflammatory  granulo ma formation in pat ients.  An inflammatory  granulo ma in the Medtronic 
surveillance study  was defined as “an intradural extra -medullary mass at the catheter tip that 
could be visualized by enhanced MRI imaging.”  The criter ia for diagnosing such a 
granulo matous m ass is based on several clinical signs and symptoms: a decrease of drug effect 
and new radicular pain and/or cord compression, MRI findings of an enhancing mass at the 
catheter ti p on the T -1 infusio n and surgical or histol ogical confirmat ion.
From  2003 to 2010 six (6) cases of confirmed or probable inflammatory  granulo ma were noted 
as well as six (6)cases of possible granulo ma out of the 4,384 patients evaluated (12/4384, 
0.27%).  All of these patients were being tr eated with intrathecal morphine for severe, intractable 
pain.  Of particular note is that no cases of a granuloma (possible, probable or confirmed) were 
docum ented in the 1,283 patients who were receiving baclo fen (0.0%).  While it is well known 
that a sig nificant am ount of pharmacy co mpounding occurs to provide concentrations of baclo fen 
up to 4 mg/mL in routine use, the number of patients receiving doses of baclo fen above 2 mg/mL 
or multiple m edicati ons is not provi ded in the report.  Thus, while the study clearly  dem onstrated 
that IT baclo fen is not associated with inflammatory granulo ma formation, and that the risk is far 
less than with IT m orphine or m orphine rel ated drugs used in the SynchroMed®II Programmable 
Pump, no definite conclusio ns can be reac hed about the ris k of the concentrati ons above 
2mg/mL from this study . 
These data are further supported by  published lit erature studi es in peer reviewed journals that 
suggest inflammatory  granulo ma formation is not a significant risk wit h baclo fen even a t 
concentrations above 2 mg/mL (see the FDA Summary  Basis of Approval for Gablofen®
(baclo fen inject ion) review pages 41 -49 and (Deer et al., 2008) ). The use of pharmacy  
compounded concentrati ons of baclo fen above 2 mg/mL is co mmo n, but not well documented. 
The dangers of compounding of baclo fen have been well illustrated (Moberg -Wolff, 2009) but 
inflammatory  granulo mas seem to occur only when opiates are co -infused with baclo fen (Deeret 
al., 2008).  
Medtroni c has correctly  warned physicians using IT baclofen therapy  to avoi d higher 
concentrations above 2 mg/mL given th e implicat ions of off label use, despite having no well 
docum ented cases of inflammatory  granulo ma formation in the FDA AERS database or 
published in the literature ( PubMed search 8 -2011).  While no well -documented cases have been
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 16 CONFIDENTIALreported, i n a publ ished review arti cle by  Deer et al.,three (3) cases of possible inflammatory 
granulo ma formation are reported based on reduce dflow of solution through the catheter (Deer
et al., 2008 ). However, he concludes that these cases cannot be confirmed as the reports did not 
included any  confirming pathol ogy, no T -1 enhancing mass at the catheter tip and no 
neuro logical signs of cord com pressi on.  The  Deer et al. review arti cle also noted that the only 
clinical co mplication was a gradual decrease in efficacy in the three (3) cases which was 
resolved by mo ving or changing the catheter to re -establish drug delivery .  Thus, Deer and co -
authors conclude that these cases were more likely due to “poor distribution o f baclo fen in the IT 
space where arachnid loculat ions, adhesio ns or encasement of the catheter ti p are assumed to be 
the problem”.  It is important to note in evaluat ing clinical risk in these three (3)cases that even 
with reduce catheter flow, there were no symptoms of sudden withdrawal from baclo fen and the 
patients were adequately trea ted wi thout any  long term  negative clinical effects.
Thus, there is no clear signal in clinical trials, published literature, or 1 9years of commercial use 
of IT bacl ofen that inflammatory  granulo ma formation is a m eaningful  clinical risk.  It i s also 
well known that phy sicians and pharmacists routinely provide higher concentrations of 
compounded baclo fen for use in the SynchroMed®II Programmable Pump and other IT pumps.  
The ri sk of these compounded formulat ions that are not manufactured under GMP conditi ons 
and controlled for sterilit y woul d seem to present a more significant risk to patients than the 
undetectable risk of inflammatory  granulo ma formulation in this population (Moberg -Wolff,
2009 ).  Given the effect iveness of baclo fen in the management of severe spast icity of cerebral 
and spinal origin in adult and pediatric patients, the risk benefit profile for the use of this product 
provi des the importance of replacing compounded higher strength formulat ions wit ha 
well-controlled commercial product would seem posit ive.
Mallinckrodt has developed a 3 mg/mL concentratio n of Gablo fen®(baclo fen inject ion)to meet 
the needs o f patients on hi gh daily  doses and proposes this open labelsafet y surveillance study  to 
assess the potential for complications related to this higher concentration formulat ion.
1.2 Nonclinical Assessments
1.2.1 Pharmacology
The precise mechanism o f action of baclo fen as a muscle relaxant and ant i-spast icity agent i s not 
fully understood. Baclo fen inhibit sboth m onosynapti c and polysynapt ic reflexes at the spinal 
level, possibly  by decreasing excitatory neurotransmitter release from primary afferent terminals, 
although act ions at supraspinal sites may also occur and contribute to its clinical effect. Baclo fen 
is a structural analog of the inhibitory  neurotransmitter gamma -amino butyric acid (GABA), and 
may exert its effects by st imulat ion of the GABA Breceptor subt ype. Baclo fen when introduced 
directly into the intrathecal  space permits effect ive CSF concen trations to be achieved with 
resul tant pl asma concentrations 100 times less than those occurring with oral administration. In 
peopl e, as well as in animals, baclo fen has been shown to have general CNS depressant 
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 17 CONFIDENTIALproperties as indicated by  the producti on of sedat ion with tolerance, somno lence, ataxi a, and 
respi ratory  and cardio vascular depression. 
1.2.2 Toxicology
1.2.2.1 Mutagenic and Carcinogenic Toxicity
No increase in tumors was seen in rats receiving baclo fen orally for two (2)years at 
appro ximately 30 -60 times o n a mg/ kg basis, or 10 -20 times on a mg/m2basis, the maximum 
oral dose recommended for human use.  Mutagenicit y assays wit h baclo fen have not been 
perform ed.
1.2.2.2 Genetic and Teratogenicity Studies
Specific genetic, fetal and post -natal toxicit y studies have not been performed wit h baclo fen.  
While the intrathecal route of administration gives low systemic exposure relat ive to oral 
baclo fen, the potential for genetic or teratogenic effects cannot be ruled out .  
1.3 Clinical Experience
Evidence supporting the efficacy of intrathecal baclo fen was obtained in rando mized, controlled 
investigat ions that com pared the effects of either a single intrathecal dose or a three (3) day 
intrathecal infusio n of intrathecal baclo fen to placebo in pat ients with severe spast icity and 
spasms due to either spinal cord trauma or mult iple sclerosis. Intrathecal baclo fen was superior 
to placebo on both principal outcome measures employ ed: change from  baseline in the Ashworth 
rating of spast icity and the frequ ency of spasms. 
The efficacy of intrathecal baclo fen was investigated in three (3) controlled clinical trials; 
two(2) enrolled pat ients with cerebral palsy  and one enrolled pat ient with spast icity due to 
previous brain injury . The first study ,a rando mized controlled cross -over tri al of 51 pati ents 
with cerebral  palsy, provi ded strong, stati stically significant results; intrathecal baclo fen was 
superi or to pl acebo in reducing spasticit y as measured by  the Ashworth Scal e. A second 
cross -over study  was co nducted in 11 patients with spasticit y arising from  brain injury . Despite 
the small sample size, the study  yielded a nearly significant test statist ic (p= 0.066) and provided 
directionally  favorable results. The l ast study , however, di d not provi de data that could be 
reliably  analyzed.
1.4 Study Rationale
The rati onale for the proposed open -label clinical safet y surveillance study  is to obtain safet y 
data on a new higher concentration (3 mg/mL) of Gablo fen®(bacl ofen inject ion).  The study  will 
provi de safet ydata on at least 100 patients receiving the high concentration formulat ion for at 
least 12 m onths in support of a market ing authorization applicat ion to the US Food and Drug 
Administrati on.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 18 CONFIDENTIALThe study  design allows participants to utilize ahigher strength concentration of Gablo fen®
(baclo fen inject ion),which will allow less frequent pump refills.  The study  is open -label and as 
such all subjects will benefit fro m the higher strength formulation.  Subjects will be mo nitored 
for safet y at least e very 6-months.  While there is no expectation that complicat ions will occur, if 
there are clinical signs of an inflammatory  granulo ma the subject will be asked to have an MRI 
to confirm the presence of a granulo ma or to ident ify the cause of the symptoms which may be
related to a blocked catheter or other pump related complicat ion.
Thus, the study  will provi de adequate clinical safety  data to all ow for approval  of this higher 
concentration formulat ion of Gablo fen®(baclo fen inject ion) that is manufactured under GMP 
control s and is a safer alternat ive to current pharmacy co mpounded products.
2.0 PURPOSE AND STUDY OBJECTIVES
2.1 Purpose
The purpose of this study  is to confirm the safet yand frequency of inflammatory  granulo ma
from a 3 m g/mL form ulation of Gablo fen®(baclofen inject ion).
2.2 Study Objectives
2.2.1 Primary Objective
The primary  object ive of this safet y and post -approval surveillance study  is to obtain data on the 
rate of inflammatory  granulo mas in pat ients given Gablo fen®(bacl ofen inject ion) 3m g/mL by  
the intrathecal rout e of administration.
2.2.2 Secondary Objectives
The secondary  objectiv e of this study  is to eval uate the overall safet y data on 3 m g/mL 
Gablo fen®(bacl ofen inject ion)given by  the intrathecal  route of administration.
3.0 STUDY DESIGN
3.1 Description of Trial Design
This is a prospective twelve -month Phase III bclinical safet y trial followed by  a 2-year, Phase IV 
study  that will be conducted at 10 to 15 clinical trial sites that are experienced wit h the use of 
intrathecal baclo fen.  All patients will be entered after sign ing an IRB approved informed 
consent. Patients will be fo llowed f or the durati on of  their treatm ent wi th Gabl ofen®(baclofen 
inject ion) 3mg/mLusing the SynchroMed®IIProgrammable Pump or until the study is 
terminated.  Patients will be evaluated for clinical complicat ions associated with the use of 
intrathecal baclo fen that are considered signs and symptoms of an inflammatory  granulo ma, 
specifically new radicular pain at the level o f the catheter tip, and/or spinal cord compression.  
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 19 CONFIDENTIALReports will be requested from the invest igator at every clinical visit for the first 12 months for 
each patient enrolled and then every  6 months thereafter. If there are any signs or sym ptoms 
ident ified which may indicate an inflammatory granulo maformation, an MRI scan with and 
without infusio n will be performed (with consent of the pat ient) to evaluate the potential 
presence of an inflammatory  granul oma. Events that may be related to a n inflammatory 
granulo ma will be classified as definite granul oma, possible granul oma, or other catheter related 
probl em (confirmed not caused by  a granul oma) or other clinical sequelae caused by the 
underlying disease or infusio n system related event. Aninterim analysis will be conducted when 
100 subjects on the 3 mg/mL concentration of Gablo fen®(bacl ofen inject ion) reach 9 months of 
treatm ent.  Addit ionally , a safet y update will be provided to the FDA after the first cohort of 
100patients reach 12 m onths.  Thereafter, annual reports to the NDA will be generated and 
provi ded to the FDA as part of this 3 year program.
3.2 Study Endpoints
3.2.1 Primary Endpoint
The pr imary endpo int is rate of definite inflammatory  granulo masduring the first 12-months of 
therapy following the init iation o f treatm ent wi th a 3 m g/mL form ulation of Gablo fen®(baclofen 
inject ion).
A confirmed inflammatory  granulo ma or m ass is one where there are clinical signs and 
symptoms of an inflammatory  granulo ma, and an intrad ural extra- medullary mass is verified by 
enhancement on an infus ionMRI.   If only clinical signs and symptoms are identified, and no 
other assignable cause can be ident ified, the event will be recorded as a possible inflammatory  
mass.
3.2.2 Secondary Endpoints
The secondary  endpoint of this study  is to assess the overall safet y during the first 12 -months of 
therapy  following the init iation o f treatm ent wi th a 3 m g/mL form ulation of Gablo fen®(baclo fen 
inject ion).
3.3 Diagnosis of an Inflammatory Granuloma 
The use of intrathecal opioids has been associated in rare case swith an inflammatory  granulo ma
at the catheter tip that can result in serious neurological impairment, including paralysis.  
While these events have not been reported with commercial baclo fen that has been unaltered by  
pharmacy co mpounding, the potential for an inflammatory granul omawith higher concentrati ons 
of bacl ofen has not been assessed.  In this study , the potenti al for an inf lammatory  granulo ma or 
mass will be assessed at each visit to the invest igator.  
Clinical signs and symptoms that may indicate an inflammatory  granul omainclude:
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 20 CONFIDENTIALoa sudden decrease in therapeut ic response requiring increased daily doses that is not 
attribu ted to other assignable causes (e.g. mechanical failures, catheter movement or 
catheter bl ockages)
ochange in the character, qualit y, or intensi ty of spasti city
ounexplained pain at the dermatomal level o f the catheter ti p
ounexplained neuro logical deficit or dysfunct ionthat coul d be caused by mass effect at 
the spinal level o f the catheter ti p
For the purpose of this study , to establish that there i s a definite inflammatory  granulo ma, an 
infusio n MRI must dem onstrate an intradural extra -medullary mass near t he catheter tip .  If only 
clinical signs are detected, but the inflammatory  granulo ma or m ass cannot be verified by  MRI, 
and no other cause can be determined, the event will be classified as a possible inflammatory  
granulo ma.    
If in the opinio n of the i nvest igator there is a reasonable probabilit y that the subject may  be 
experiencing an inflammatory  granul oma, an MRI without and with infusio n of a contrast agent 
will be requested.  All MRIs will be assessed by  a single central  independent radio logist who
will be blinded to the patient’s history .  
3.3.1 Treatment of an Inflammatory Granuloma
If an inflammatory  granulo ma is detected early in its clinical course, d epending upon an 
individual pat ient's clinical condit ion, intraspinal therapy may be cont inued after one of the 
following interventions: 
oWithdraw the catheter to a level below the inflammatory granulo ma. 
oRemove the involved catheter and replace it with a new catheter posit ioned below the 
inflammatory  granulo ma. 
oDisconnect the involved catheter from th e connector (two -piece catheter), or transect 
the invo lved catheter above the level of the lumbo -dorsal  fascia (one -piece catheter) 
leaving the intraspinal catheter segment undisturbed. Ligate the exposed end of 
involved catheter to prevent CSF loss. Implant a new catheter with its tip below the 
inflammatory  granulo ma, and connect the new catheter to the proximal (pump) 
catheter segment. 
Prom pt open surgical remo val o f the granulo maor decom pressio n of the spinal cord should be 
considered in patients who have a significant or progressive neuro logical deficit. 
Regardless of intervent ions, if a granulo ma is detected, the subject should be discont inued fro m 
this invest igational tri al and treated wi th convent ional baclo fen therapy .
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 21 CONFIDENTIAL3.4 Measures to Minimize Bias
3.4.1 Blinding
This study  isnot randomized and has no concurrent con trols. Study  drug will  be administered in 
an open -label fashio n.
3.4.2 Assignment to Study Drug
Each subject who is determined to be eligible for the study  will b e assi gned a unique treatm ent 
number consist ing of S for the site number and a three -digit subject number (SXX-XXX) by  the 
by the study  coordinator or designee. The subject number will be sequent ial at each clinical site
3.5 Study Drugs
3.5.1 Rationale for Doses and Dosing Regimen
All subjects enro lled in this trial will be on a stable current dose of intrathecal baclofen 2 m g/mL .  
A stable dose of baclo fen for the purpose of this trial will be defined as adequate symptom 
control  with no m ore than a 20% change in da ily dose over a 30 day  period.  Study  partici pants 
will be switched to the 3 mg/mL formulat ion of Gablo fen®(bacl ofen inject ion) at their current 
daily  dose of bacl ofen.  Dose adj ustments may be permi tted ten (10) day safter the swi tch to 
3mg/mL Gablo fen®(baclo fen inject ion) as needed according to standard of care ,however, the 
daily  dose will not exceed 2000 mcg.
3.5.2 Dosages and Dosing Regimen
3.5.2.1 12-Month Course of Treatment
Subjects in this trial will be enro lled at their current stable dose of baclo fen.  Doseadjustments 
will be permitted after ten (10)days on the 3 m g/mL Gablo fen®(baclofen inject ion) formulation.  
The subject shall return to the investigational site for evaluation at least at 6, 9 ,and 12 months 
(±7days).  More frequent visits may be neces sary for pum p refills depending on the dose of 
baclo fen administered daily.
3.5.2.2 Continuation of Therapy
In the absence of any  significant si de effects or other com plicati ons, treatm ent wi th Gabl ofen®
(baclo fen inject ion) 3 mg/mL may  cont inue after the init ial 12-month peri od for up to a total of 
36 m onths.  During the 24 -month extension o f therapy , subjects m ust return to the clinical site at 
least every  6months for evaluat ion and pump refills.  More frequent visits may  be requi red f or 
very high daily  dose tre atments where the pump will have t o be refilled more than every 
6months.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 22 CONFIDENTIAL3.5.3 Dose Modifications
Dose m odificat ions are permitted after 10 day son the 3 m g/mL Gablo fen (baclo fen injection) 
formulation.  Dose m odificat ions will be done according to standard of care for pati ents on 
intrathecal baclo fen.  Given that the daily dose is not impacted by  use of the higher concentration 
of Gablo fen®(baclofen inject ion), no speci al dosing instructions are provided.  Please see the 
current approved Gablo fen®(baclo fen inject ion) product labeling for dose modification 
instructi ons.
3.5.4 Dose Interruption
Dose interruptions are permitted for up to 10 continuous days for subjects on this clinical tri al.  
This dose interruption may be necessary  to correct catheter fail ures, repl ace pum ps, to all ow for
a drug holiday or other m edically  docum ented reasons .  Any dose interruption that exceeds 
10consecutive days will result in the subject being discont inued fro m the study , unless approved 
in advance by  the Medical  Moni tor.  Oral baclo fen therapy  may be prescribed at any  time during 
an intrathecal medicat ion dose interruption, surgical procedure or post -surgery  period until the 
subject is stabilized on intrathecal baclo fen therapy.
3.5.5 Pump or Catheter Replacements
Pump or cathe ter repl acements are permitted in this trial due to mechanical malfunct ions, battery  
failures or other related mechanical reasons.  The Medical Monitor should be notified if any 
subject requires a surgical procedure to correct a catheter failure or require s a pum p repl acement.  
If a subject requires a pump replacement or catheter replacement, dose interrupti ons for up to 
10days are permitted while the procedure is conducted and until study  drug can be repl aced into 
the new pump.  If the pump is removed, study drug wi thin the pum p shoul d be removed and the 
volume rem oved entered on the drug accountabilit y log. When the pum p is repl aced, refill wit h 
investigat ional product from a new sy ringe of  3 mg/m L baclo fen.  After the pump or catheter 
replacement, at th e discret ion of the invest igator, subjects may be restarted at their previous dose 
of bacl ofen or a reduced dose and titrated back to an optimal dose as part of normal standard of 
care for that subject.   Oral baclo fen therapy  may be prescribed at any  time during an intrathecal 
medicat ion dose interruption, surgical procedure or post -surgery  period unt il the subject is 
stabilized on intrathecal baclo fen therapy .
For pum p repl acements that are performed at a medical inst itution that is unaffiliated with the 
study  invest igator’s site, the invest igator is responsible ensuring that study  drug is rem oved from  
the pump and the waste is accounted for on the drug accounta bility log.  The Invest igator is 
responsible for contacting the responsible clinician performing the pump replacement to ensure 
they are aware the subject is invo lved in a clinical trial.  After the surgery , the pum p shoul d be 
filled with either 2 mg/mL co mmercial (i.e. FDA approved) baclo fen or saline unt il the subject 
can return to the invest igators site to have the baclofen replaced with 3 mg/mL invest igational 
product.  If the subject cannot return to the invest igators site within 10 days of a dose 
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 23 CONFIDENTIALinterrupti on they  will be di scontinued from the study  unless a longer dose interruption period is 
approved by  the Medical Monitor in advance.
3.6 Concomitant Medications
3.6.1 Prior and Concomitant Medications
Prior medicat ions are defined as medicat ions that were taken within 30 days of theinitial dosing 
with study  drug. 
Concomitant medicat ions are defined as medicat ions taken any  time after the start of do sing 
through the 12 m onth visi t.  Concomitant m edicat ions are not collected after 12 months as part of 
this proto col. 
There i s inadequate experience wit h the use of intrathecal baclo fen in co mbinat ion with other 
medicat ions to predict specific drug -drug interactions. Interacti ons attributed to the combined 
use of intrathecal baclo fen and epidural morphine include hypotension and respi ratory  
depressio n.
3.6.2 Prohibited Concomitant Medications
It is prohibited to combine as one solut ion for intrathecal administration, Gablo fen®(baclo fen
inject ion) wi th other drugs.  There are no other prohibited medications given by routes of 
administration other than intrathecal infusion.
3.7 Duration of Therapy
In the absence of an inflammatory  granul oma or drug related SAE ( serious adverse drug 
reaction) subjects in this trial may  continue on treatm ent wi th 3 mg/mL Gablo fen®(bacl ofen 
inject ion) for up to 36 months.  An interim analysis will be conducted after 9 and 12 months of 
therapy .
3.8 Procedures for Monitoring Subject Compliance
Subjects wil l return to the clinic for safet y evaluations and pump refills at l east every  6 months 
or as dictated by  their daily  dose and need to refill the infusion pump .  Subject swill also return at 
the 9-month time po int for eval uations, even if the pump does not require refilling.  Subjects who 
do not comply  with the visit schedule will be discont inued fro m the study  and pum p refills 
continued wit h the approved concentrations of Gablo fen®(bacl ofen inject ion). 
4.0 STUDY POPULATION
Male or female subjects 4 years o f age or ol der wi th severe spast icity and requi ring intrathecal 
baclo fen.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 24 CONFIDENTIAL4.1 Inclusion Criteria
Subject smust meet all of the fo llowing cri teria to be eligible for this study : 
1. 4 years of age or older .
2. M ust be clinically  diagnosed wi th severe spast icity and are receiving intrathecal baclo fen.
3. M ust have a SynchroMed®IIPump already implanted.
4.Current treatment with intrathecal baclo fen shoul d be at the 2 m g/mL concentrati on.
5.Life expectancy  12 m onths .
6.Signed wri tten informed consent .
7.Abilit y and willingness to com ply wit h the study  protocol  for the durati on of  the study  
and wit h follow-up procedures 
4.2 Exclusion Criteria
Subjects who meet any  of the f ollowing cri teria will be excluded fro m participat ion in the study :
1.History  or presence of malignancy, wi th the excepti on of adequately treated localized 
skin cancer (basal cell or squamous cell carcino ma) or carcino ma in-situ of  the cervix, 
which is allo wed
2.History  of any allergic react ion to baclofen
3.History  of inflammatory  granulo mas wit h an intrathecal infusio n pum p
4.Any previous history  of neuroleptic m alignant syndrom e or m alignant hyperthermia
5.As a result of medical review and physical examination, the Invest igator considers the 
subject unfit for the study
5.0 SAFETY ASSESSMENTS
5.1 Collection o f Adverse Events Data
Data regardi ng treatm ent-emergent AEs will be collected in this study . Treatment -emergent AEs 
are events that are not present at b aseline, or if present at baseline, have worsened in severit y. 
AEs will be assessed at each study  visitfrom the time of study  drug administration on Study  
Day 1through the final visit. AEs asses sed by the Invest igator as related to study drug and 
“ongoing” at the final scheduled study  visit will be monitored by  the Invest igator until reso lved 
or stabiliz ed.
Each subject will be observed and queried by  the Investi gator or hi s/her designee at each study  
visit for any  cont inuing AEs or new AEs since the previous visit. If an AE occurs between study 
visits, regardless of causal relat ionship to study  drug and in the opinio n of the Invest igator, 
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 25 CONFIDENTIALrequi res a study  visit for full evaluat ion, the subject will be asked to return to the sitefor an 
unscheduled visit. 
Any AE reported by  the subject or noted by  the Investigator or his/her designee will be recorded 
on the CRF. The fo llowing inform ation will be recorded for each AE: descript ion of the event, 
date and time of onset, date and time of reso lution, severit y, causal  relat ionship to study  drug, 
outcom e, acti on taken wi th the study  drug and any treatment given.
All abnorm al changes from baseline in physical ex aminat ion findings, vital signs will be 
collected, graded with regards to severit y or clinical significance and asses sed f or causal  
relationship.
5.2 Physical Examinations and Medical History
5.2.1 Complete Physical Examination
The Investigator or designee will perform a co mplete phy sical examinat ion at screening. Results 
will be recorded as part of the subject’s Medical History .Assess ments of height, weight, and 
vital signs will be collected as part of the sites standard of care and recorded on the subject ’s 
medical records .  Assessments collected as part of standard of care, may be co llected prior to the 
subject signing aninformed consent if not conducted specifically for the purpose of this clinical 
trial.  For subjects who are nonambulatory  weight and height are not required to be collected if 
not possible. Any underlying medical condit ion will  be recorded as ongoing baselin e events for 
future assessment of adverse events or serious adverse events.  Only adverse changes fro m this 
baseline condit ion will be considered adverse events or serious adverse events.
5.2.2 Targeted Physical Examination
A targeted physical examinat ion, focus ing on areas related to the reported AEs, will be obtained 
by the Invest igator (or designee) during study  visit s when an AE or SAE are reported . 
Atargeted physical examinat ion will  also be perfo rmed at the final study  visit, if clinically 
warranted by  the presence of an AE.
All abnorm al changes from baseline will be collected, graded with regards to severit y, assessed 
with regards to causalit y and recorded in the CRF to be reported as abnormal physical 
examinat ionfindings.   Only clinically significant a bnorm al findings are considered to be AEs 
and will be recorded in the subject’s medical record and in the CRF.
5.2.3 Medical History
A medical history  will be obtained at screening. Medical history  will include dem ographic data 
(age, gender, race/ethnicit y, etc. ). In addition to general medical condit ions, specific information 
relative to the underlying disease that resulted in severe spast icityrequi ring an intrathecal pump 
will be obtained and recorded in the CRF:
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 26 CONFIDENTIALUnderlying disease result ing in spast icity, date of init ial diagnosis, and prior treatments
within the past 12 months .
Date of implantati on of  an intrathecal  pum p.  If  more than one pum p has been implanted 
the date of each implantation is requested.
Date of surgical interventions for treatment spastici ty.
Other si gnificant m edical history .
5.3 Vital Signs
Vital signs will  be collected on all subjects at screening, baseline and each study  visit.  If the 
screening and baseline visit s are combined, vital signs will be collected as part of the sites 
standard of care fr om the subject’s medical records.  T hesedata maybe collected prior to the 
subject signing the informed consent if the assessment is part of the normal standard of care, and 
not specifically  being conducted as part of this clinical protocol . 
Sites shoul d make every  effort to collect a full set of vital signs on each subject post screening 
and baseline.  Should the site have difficult ies co llecting vital signs on subjects due to their 
underlying disease condit ion or the cooperation of the subje ct, the si te will be required to 
docum ent in the subjects source records the attempts made and report on the CRF “NE” 
(notevaluable ) for vital sign assessments that could not be ob tained .
5.4 Documentation of Concomitant Medications
Details regarding the nam e, indicat ion, dose, route of administration, and frequency o f all 
prescri ption medications, will be documents from 30 day s prior to dosing and through the first 
12months after ini tiation of study  medicati on as part of this protocol .
6.0 PHARMACOKINETICS
No pharmacokinet ic assessments are planned during this trial.
7.0 PHARMACODYNAMICS
No pharma codynamic assessments are planned during this trial.
8.0 EFFICACY
No formal efficacy analysis is planned during this trial .  However, the daily  dose of Gabl ofen®
(baclo fen inject ion)used will be recorded for each patient in the trial.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 27 CONFIDENTIAL9.0 STUDY VISITS
Refer to Appendix Afor the Schedule of Study  Procedures.
9.1 Screening
The Investigator or his/her approved designee must explain the nature of the study protocol and 
associ ated risks to the potential study  parti cipant. The potential participant must be allowed to 
review the study  informat ion and to ask questions before bein g asked to si gn the Inform ed 
Consent Form. Written informed consent must be provided by the potential study  parti cipant or 
legal guardian prior to init iation of any screening evaluat ions or other study -related procedures. 
The signature date and the name o f the individual at the site who obtained the informed consent 
will be recorded in the subject’s medical record. 
After wri tten inform ed consent i s obtained, the subject will be assigned a five-digitnumber
(SXX -XXX) and will undergo the designated screeni ng procedures listed in Appendix Awithin 
14days prior to study  drug admin istrati on. The Investigator , or his designee, will assess the 
resul ts of these screening evaluat ions to determine eligibilit y for entry  into the study  according to 
the inclusio n/exclusio n criteria listed in Secti on  4.0.
9.2 Baseline Evaluations
Note that the Baseline and Screening evaluat ions may be combined at one visit.  Baseline 
assessments that are considered standard of care (SOC) may be performed prior to consent of the 
subject and are not required to be repeated if conducted on the same day  of enrollment.  If the 
subject is determined to be eligible for participat ion in the study  they will undergo baseline 
assessments. Baseline assessments are assessment of concomitant medicat ions, complete 
physical examinat ion, wei ghtandvital signs .At the baseline visit, the remaining baclo fen 2 
mg/mL product in the SynchroMed®IIInfusio n Pum pwill be rem oved and repl aced wi th the 3 
mg/mL formulat ion.   The flow rate for the SynchroMed®IIInfusio n Pum p will be adjusted to 
maintain the patient’scurrent daily  dose of bacl ofen.
9.3 Interim Study Visits
Subjects will return to the inves tigational site approximately every  6months or sooner if 
warranted by  their daily  dose of bacl ofen for assessments and pump refills. At each study  
interim visit subjects will be assessed for AEs and clinical signs or symptoms of an inflammatory  
granulo ma.  If an AE i s reported, a targeted physical exam will be conducted to evaluate the 
severit y and causalit y of the event (See  Appendix A).
If interim visits more frequent than each 6 months are necessary  due to the daily  dose of 
baclo fen, the site should contact the Medical Monitor to request a patient specific  Appendix A
that will specify the visit dates recommended for the study .
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 28 CONFIDENTIALAll visit dates are to be conducted within 7 days of the scheduled date ( i.e. ±7days).
9.4 Final Visit
Subjects will return to the investigat ional site for the final visit after 36months or when 
discontinued fro m the study  for any  reason. At the final study  visit subjects will be assessed for 
AEs and clinical signs or symptoms of an inflammatory  granulo ma.  If an AE is reported, a 
targeted physical exam will be conducted to eva luate the severit y and causalit y of the event (See 
Appendix A).  At the final study visit, all remaining 3 mg/mL Gablo fen®(bacl ofen inject ion) 
will be remo ved fro m the SynchroMed®IIInfusio n Pum p and repl aced wi th commercial  product 
at the discretion of the Invest igator.
10.0 PREMATURE DISCONTINUATION FROM STUDY
A premature discont inuat ion from study  will occur when a subject who signed informed cons ent 
ceases participat ion in this study , regardl ess of  circum stances, pri or to com pletion of the initial 
12-month study  period. Subjects can be prematurely discont inued fro m the study  for one of the 
following reasons: 
Failure to meet inclusion/exclusio n criteria before receiving first dose of study  drug has 
been administered
Death
Significant safet y event that do esnot resolve within 7 days of lowering the dose or other 
clinical intervent ions.
Lost to follow -up after every  attem pt has been made to contact the subject including 
sending a registered letter
Subject withdraws consent
The reason for the discont inuat ion shoul d be recorded on the CRF.
The Principal Invest igator and the Inst itutional Review Board/Ethics Committee (IRB/EC) 
reserve the right to prematurely terminate the study in the interest of subject safet y and welfare. 
The Sponsor reserves the right to prematurely terminate the study  at any  time for administrative 
reasons.
11.0 PREMATURE DISCONTINUATION FROM STUDY DRUG
The Investigator will cont inue to m onitor subj ects who have discont inued prematurely fro m 
study  drug due to an AE (serious and nonseri ous) unt il reso lution or stabilizat ion of the AE. 
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 29 CONFIDENTIALThe Investigator must complete all applicable CRF pages for subjects who discont inue study  
drug prem aturely . Final visit procedures (i.e., AE assessment, concomitant medicat ions review, 
targeted physical exam, vital signs, and weight ) should be conducted for any  subject who 
discontinues study  drug prem aturely .
Subjects who prematurely discont inue study  drug for any  reason other than toxicit y may be re -
entered into the study  after consul tation between the Invest igator and the Sponsor or the 
Sponsor’s designee .  Dosing of a subject who previously discont inued in the study  isat the 
discreti on of  the Sponso r.  However, subjects who drop out due to toxicit y willnot be replaced.
12.0 PRODUCT SPECIFICATIONS
12.1 Description
Gablo fen®(bacl ofen inject ion) is provi ded in a singl e use pre-filled syringe of 60,000 m cg per 
20mL ( 3000mcg/mL) for intrathecal administration only.
The drug product is manufactured under current Good Manufacturing Practices (cGMP) at 
Cangene BioPharm a, acontract m anufacturing fa cility that has undergone FDA inspect ion.
12.2 Formulation, Packaging, and Labeling
Gablo fen®(bacl ofen inject ion) 3 mg/mL will be supplied in single use pre-filled syringe s and 
contains baclo fen, sodi um chloride and water.  Syringes will  be packaged in b oxes for shipment 
to the clinical sites.
Study  drug syringes will be affixed with a single label panel containing the following 
inform ation:
Gablo fen®(baclofeninject ion) Intrathecal
60,000 mcg / 20 mL (3,000 mcg/mL)
Lot Number:  XXXXXX
Manufacturing Date: MM- DD-YYYY
Store at Room Temperature ( 15-30℃ )
Cauti on: New Drug –Limited by U.S. Federal Law to Invest igational Use
Distributed by  Mallinckrodt Brands Pharmaceutical ,Inc.
12.3 Receipt, Storage and Stability of Gablofen
Gablo fen®(bacl ofen inject ion) 3 mg/mL syringes will be packaged in boxes for shipment to 
investigat ional sites. Excursions permitted to 4 -30C(6° to 86 °F),and after recei pt shoul d be 
stored at 15 - 30°C(59°- 86° F)until use.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 30 CONFIDENTIAL12.4 Preparation and Administration of Study Drug
There i s no m anipulat ion or preparati on of  study  drug other than filling into the SynchroMed®II
Infusio n Pum p according to the manu facturer ’s instructions .
12.5 Ordering and Distribution of Study Drug
Study  drug m ay be requested by  submissi on of a medi cation request form .  The form may be 
submitted to the Sponsor or designee by  facsimile or el ectroni c mail  PDF as per the instructions 
on th e drug ordering form.
12.6 Accountability of Study Drugs
All study  drug received, dispensed, and returned must be accounted for in the study drug 
Dispensing Log, including:
Subject number and init ials
Date study  drug was di spensed
Quant ity dispensed
Quant ity returned
Amount wasted including drug removed fro m a pump during refills or pump replacement
All study  drug received and dispensed by the Investigator will be inventoried and accounted for 
throughout the study . The study  drug m ust be stored in a restricted a rea wi th limited access. 
Contents of the study  drug containers must not be combined.
The Investigator must maintain an accurate, up to date Dispensing Log for all study  drugs 
supplied by  the Sponsor. Study  drug di spensed for all subjects must be recorded on the Drug 
Accountabilit y Form . The study  drug Di spensing Log and remaining drug inventory  will be 
reviewed during monitoring visit sby the Sponsor -designated clinical mo nitor.
The study  drug supplied for this study  is for use only  in subjects properly  consented and enrolled 
into this protocol . Study  drugs m ust be kept in a secure location physically  separated from  
standard clinic or office drug supplies.
13.0 SAFETY MONITORING AND A DVERSE EVENTS
13.1 Adverse Events
Data regardi ng treatm ent-emergent AEs will be collected in this study . Treatment -emergent AEs 
are events that are not present at baseline, or if present at baseline, have worsened in severit y.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 31 CONFIDENTIALThe descriptions and grading scal es found in the CTCAE v 4.03 will be used for AE reporting. 
A copy  of the CTCAE v 4.03 i s provi ded in  Appendix B.
The m edical  monitor and con tact information for this study  are presented below:
Yanping Zheng Director,
Clinical Affairs, 
Mallinckrodt, Inc.Office:
314-654-3 583
Cell:
314-452-1227E-mail:
yanping.zheng@mallinkcrodt.com
Evaluation of Adverse Events and Adverse Drug Reactions:
Adverse events in the Case Report Form (CRF) will be classified according to the most rec ent 
FDA definit ions and in a manner co nsistent with ICH guidelines.  As such the fo llowing 
definit ions will be used:
An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally 
associ ated wi th the use of an invest igational (medicinal) product (IP) or other protocol -imposed 
intervent ion, regardless of attribut ion.  An AE may include intercurrent illnesses or injuries that 
represent an exacerbat ion (increase in frequency, severit y, or specificit y) of pre -exist ing 
condi tions (e .g., worsening of asthma).  A laboratory  abnorm ality will be reported on the 
“Adverse Event” case report form only if it is associated with clinical sequelae or requires 
therapeuti c intervent ion.  Whenever possible, it is preferable to record a diagnosis a s the AE term  
rather than a series of symptoms relat ing to a diagnosis.  AEs will be graded according to the 
NCI Commo n Termino logy Cri teria for Adverse Events (CTCAE) v 4.03.
The reporti ng period for nonserious AEs starts after the first administration of study  drug on Day  
1and ends after discont inuat ion of study  medicat ion.
If a SAE rem ains unreso lved after discontinuation of study  medicat ion, the subject will be 
followed, at the invest igator’s discret ion, until resolut ion of the event .SAEs m ust be fo llowed 
until reso lution by the PI, even if this extends beyo nd the study -reporting period.  Resolut ion is 
defined as the return to baseline status or stabilizatio n of the condit ion with the expectati on that i t 
will remain chronic.
The invest igator will assess AEs for severit y, for rel ationship to IP, and as to whether the event 
meets one or more of the definit ions of an SAE .
The invest igator will determine the relat ionship of an AE to the IP and will record it on the 
source documents and AE CRF, using the categories of unrelated, possibly  related (ie ,reasonable 
possibilit y of causal  relati onshi passoci ated wi th use of IP ), and probably related (ie ,probably or 
known reason to con clude that use of IP caused the event) .
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 32 CONFIDENTIALIn order to classify adverse events and diseases, preferred terms will be assigned by the sponsor 
or its desi gnee to the ori ginal  term s entered on the CRF, using MedDRA.   CTC AE is provi ded in 
Appendix B.
Table 13-1: Severity Assessment Terminology for Reporting Adverse Events
(CTCAE v 4.03)
CTCAE GradeCommon 
TermDescription
1 MildMild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.
2 ModerateModerate; minimal, local or noninvasive intervention indicated; 
limiting age -appropriate instrumental Activities of Daily Living 
(ADL).
3 Sever eSever e or medically significant but not immediately life-
threatening; hospitalization or prolongation of
hospitalization indicated; disabling; limiting self-care Activities 
of Daily Living (ADL).
4Life-
ThreateningLife-threatening consequences; urgent intervention indicated.
5 Death Outcome of AE was death
For those AEs that are not described on the CTCAE v 4.03 , such AEs will be graded according 
to the same scale as defined above.
13.2 Serious Adverse Events
According to the ICH Guidelines for Good Clinical Pract ice (E6), an SAE is any untoward 
medical oc currence during the course of a clinical investigat ion that is characterized by  one or 
more of the f ollowing:
Results in death
Is life -threatening
Requi res nonscheduled (not routine or planned) in-subject hospitalization or prolongat ion 
of exist ing hospi talizati on
Results in persistent or significant disabilit y/incapacit y
Is a congenital ano maly/birth defect
Important m edical events
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 33 CONFIDENTIALAlthough not a formal SAE, exposure to study  drug during pregnancy , even if no AE is reported 
in the mother, should be reported within 24 hours as an SAE .  
For subject s who are hospitalized for a scheduled procedure or observat ionrelated to failures of 
the pump, catheter or other device malfunct ions,and where the event is not related to the study  
medicat ion,the hospi talizat ion will not be considered an SAE as part of thi s clinical tri alunless 
deem ed possibly  related to study  medicat ion by the investigator or Medical Monito r. Please 
contact the Medical Monitor prior to any  scheduled hospi talizat ion, for catheter or pum p related 
correcti ons, to determine if this event should be recorded as an SAE or will be considered routine 
standard of care .
13.2.1 Reporting Requirements for Ser ious Adverse Events
Initial Reporting
SAEs (based on FDA/ICH definit ion of an SAE) require immediate reporting to Mallinckrodt or 
designated representative. 
For all fatal or life -threatening events, the invest igator(s) or designee must report informat ion 
within 24 hours to the Medical Monitor at 334 -868-3111.
For all SAEs, the invest igator(s) or designee must complete the SAE report form wit h the 
minimum informat ion required by FDA and ICH and fax it to Mallinckrodt Pharmacovigilance 
at 314 -654-5759 within 24 hours of first knowledge of the event even if the experience does not 
appear to be related to the study  drug. 
The invest igator(s) or designee will receive acknowledgement of receipt of the SAE report form 
from Mallinckrodt.
Shoul d the invest igator(s) or desi gnee have any  difficul ty in sending the SAE report, they  may 
contact Mallinckrodt Pharmacovigilance at 1 -800-778- 7898 (24 hour call center) or email: 
globalpv@mallinckrodt.com.
If there is any doubt about whether the informat ion consti tutes an SAE, the informat ion is to be 
treated as an SAE.
Follow Up Reporting 
The invest igator(s) or designee must complete an SAE report form for all fo llow-up informati on 
received and fax it to the sponsor 314 -654- 5759 within 24 hours of receipt of addit ional or 
upda ted inform ation (eg, detailed written descript ions that include copies of relevant subject 
records, autopsy  reports and other supporting documents). The invest igator(s) or designee will 
receive acknowledgement of receipt for each SAE report form fro m Malli nckrodt.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 34 CONFIDENTIALThe invest igator(s) or designee is required to report immediately unexpected SAEs to the 
responsible IRB/IEC. 
All adverse events (serious and non- serious) occurring in subjects from the time of informed 
consent through the complet ion of the follo w-up telephone call will be documented as an AE in 
the source and in the eCRF. All fields on the AE eCRF page should be completed for each event 
with a full descri ption of the event and date and time of onset and reso lution. The invest igator 
must fo llow up on all AEs and SAEs unt il the events have subsided, until values return to within 
the acceptable range, the invest igator determines that fo llow-up is no l onger necessary, or the 
subject is referred to a nonstudy  physician.
The sponsor will report SAEs to the FDA and investigators according to local regulat ions.
Table 13–2 Reporting Requir ements for  Adverse Events
Reporting Requirements for Adverse Events
Seriousness Reporting Time Type of Report
ALL SERIOUSWithin 24 hoursInitial report on the SAE form
Appropriate eCRF
Within 24 hours of receipt of 
follow -up informationFollow up/final report on the 
SAE form
NON- SERIOUSPer case report form submission 
procedureAppropriate eCRF
Table 13–3Contact Information for SAE Reporting
Contact Information For SAE Reporting
Mallinckrodt Global Pharmacovigilance:  
Office Fax: +1-314-654-5759
24-Hour Call Center
Telephone: +1-800-778-7898
Email: GlobalPV@mallinckrodt.com
13.2.2 Recording of Serious Adverse Events
All SAE information must be recorded on the SAE form provided by the Spo nsor. Addit ional 
follow-up inform ation (e.g., test results, autopsy , and discharge summary ) may be requested to 
supplement the SAE report form and can be attached as de -ident ified records . A copy  of all 
initial and fo llow-up reports m ust be filed with the subject’s medical records.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 35 CONFIDENTIAL14.0 STATISTICAL CONSIDERATIONS
14.1 Sample Size Determination
Up to 150 subjects will be enrolled at up to fifteen(15) invest igative sites. The sample size for 
this study is not based on statist ical consi derati ons. The sample size was selected to ensure that 
100subjects will remain in the study  for 12 -months of evaluation .
14.2 Analysis Data Se ts
Subjects who receive at least one dose of Gablo fen®(baclo fen inject ion)3 mg/mL will be 
included in the safet y analyses. 
Subjects that con tinue on therapy and com plete a 12-month course of therapy will be included in 
the assessment for inflammatory  granulo mas.
14.3 Data Analyses
Data will be presented as summary statist ics for each dose group and each product used.  The 
intent-to-treat (ITT) populat ion includes all pat ients who were deemed eligible, have signed the 
inform ed-consent form  (ICF), have been i mplanted wi th the SynchroMed®II Programmable 
Pump and treated with baclo fen. The evaluable (or “per protocol”) population is the subset of 
ITT patients who were deemed eligible, signed the ICF, have been clinically evaluated for 
inflammatory  granulo ma formation through a physical examinat ion and evaluat ion of the 
investigator.
The incidence of inflammatory  granul omas, suspected granulo mas, and other catheter related 
events will be compared by  a paired two -tailed T -test between each of the treatment groups .  
Results will be summarized in 9 -month and 12- month interim reports and included in the overall 
study  final report at the end of 3 y ears.
14.4 Safety
Safety data will be presented as summary and descriptive statist ics, and will be provi ded f or 
actual values a nd change fro m baseline values for vital signs 
The incidence and severit y of AEs reported during the study  and thei r relati onship to study  drug 
will be tabulated. AEs will be coded using the Medical Dict ionary for Regul atory  Activit ies 
(MedDRA™) and the CTCAE v 4.03, and will be presented by body  system and preferred term . 
The Worl d Heal th Organizat ion Drug Di ctionary (WHOD D) will  be used to cl assify  prior and 
concomitant medicat ions by therapeut ic class and preferred term. Prior and concomitant 
medicat ion usage will be summarized by  the number and percentage of subjects receiving each 
medicat ion within each therapeut ic class.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 36 CONFIDENTIALSafety analyses will be presented by age group (pediatric and adult) and for all subjects.
14.5 Preliminary Efficacy
Efficacy will not be assessed in this trial.  However, summary statist ics on the daily dose of 
baclo fen and changes in dose of baclo fen will be summarized in the clinical study report .
15.0 DATACOLLECTION, STUDY MONITORING, AND DATA DISCLOSURE
15.1 Data Collection and Reporting
A CRF will be co mpleted for each subject who receives at least one dose of study  drug. All 
entries on the CRF must be supported by  original  source docum entati on (e.g., laboratory  reports, 
medical records) maintained at the invest igational si te. 
The Inves tigator will review all safet y assessments (AEs , vital signs, and results from physical 
examinat ions) on an ongoing basis. The Invest igator is required to review all entries on the CRF 
and sign at appropriate time intervals.
15.2 Study Monitoring
All aspects o f the study  will be monitored carefully  by the Sponsor’s designees wit h respect to 
current Good Clinical Pract ice and Standard Operating Procedures for compliance with 
applicable government regulat ions. It is the responsibilit y of the Invest igator to provi de all  study  
records, including CRFs, source documents, etc., for review and inspect ion by the clinical 
monitor.
All CRFs will be 100% source verified against corresponding source documentation (e.g., office 
and clinical laboratory  records) for each subjec t. Clinical mo nitors will evaluate periodically the 
progress of the study , including the verificat ion of appropriate consent form procedures, review 
of drug accountabilit y and preparati on procedures, adherence to dosing procedures, and the 
verification o fthe accuracy  and com pleteness of CRFs. Clinical mo nitors will also ensure that all 
protocol  requi rements, applicable FDA regulat ions, other requirements, and Invest igator’s 
obligat ions are being fulfilled.
15.3 Data Disclosure and Subject Confidentiality
Subje ct medical  information obtained as a result of this study  is consi dered confident ial. 
Disclosure to thi rd parti es other than those noted below is prohibited. All reports and 
communicat ions relat ing to subjects in this study  will identify each subject only by their init ials 
and number. Medical informat ion result ing from a subject’s participation in this study  may be 
given to the subject’s personal physician or to the appropriate medical personnel responsible for 
the subject’s welfare. Data generated as a resul t of this study  are to be available for inspect ion 
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 37 CONFIDENTIALon request by  FDA or other government regulatory agency auditors, the Sponsor clinical mo nitor 
(or designee), and the IRB/EC.
All laboratory  specimens, evaluat ion forms, reports, and other records tha t leave the site will be 
ident ified by a coded number to maintain subject confidentialit y. All records will be kept in a 
locked file cabinet. All co mputer entry  and networking programs will be identifiable only  by 
coded numbers. Clinical information wil l not be rel eased wi thout wri tten permissio n from the 
subject, except as necessary for monitoring by the IRB, the FDA, or the study  Sponsor. 
Any informat ion, inventi ons, or di scoveri es (whether patentable or not), innovat ions, 
suggest ions, ideas, and repo rts, m ade or developed by  the Invest igator(s) as a result of 
conducting this study  shall  be prom ptly disclosed to the Sponsor and shall be the so le property of 
the Sponsor. The Invest igator agrees, upon the Sponsor’s request and at the Sponsor's expense, 
to execute such documents and to take such other actions, as the Sponsor deems necessary or 
appropriate, to obtain patents in the Sponsor’s name covering any of the foregoing.
The results of this study  will be published under the direction of the Sponsor. Results will not be 
published wit hout pri or review and approval by the Sponsor.
16.0 PROTECTION OF HUMAN SUBJECTS
16.1 Declaration of Helsinki
The study  will be conducted in accordance with the Declarat ion of Helsinki (1964) including all 
amendments up to and inclu ding the South Africa revisio n (1996).
16.2 Institutional Review Board/Ethics Committee
The Investigator agrees to provide the IRB/EC with all appropriate material, including a copy  of 
the Informed Consent Form. The study  will not be init iated unt il the Invest igator obtains written 
approval  of the research pl an and the Inform ed Consent Form fro m the appropri ate IRB/EC and 
copies of  these docum ents are received by  the Sponsor. Appropriate reports on the progress of 
this study  will be made by the Investigator to the IRB/EC and Sponsor in accordance wit h 
applicable government regulat ions and in agreement with the policies established by the 
Sponsor. The Sponsor ensures that the IRB/EC complies wit h the requirements set forth in 
21CFR Part 56 .
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injectio n) Version:  2.0
18 December 2014 38 CONFIDENTIAL17.0 REFERENCE LIST
Deer, T. R., L. J. Raso, et al. (2008). "Intrathecal baclo fen and catheter tip inflammatory  mass 
lesions (granul omas): a reevaluat ion of case reports and imaging findings in light of 
experimental, clinicopathological, and radio logical evidence." Pain Med 9(4): 391 -395.
Dzitoyeva, S., N. Dimitrijevic, et al. (2003). "Gamma -amino butyric acid B receptor 1 mediates 
behavior -impairing act ions of alcoho l in Drosophila: adult RNA interference and 
pharmaco logical evidence." Proc Natl  Acad Sci  U S A 100(9): 5485 -5490.
Mezler, M., T. Muller, et al. (2001). "Cloning and funct ional expressio n of GABA(B) receptors 
from Drosophila." Eur J Neurosci 13(3): 477 -486.
Moberg -Wolff, E. (2009). "Potential clinical impact of compounded versus no ncompounded 
intrathecal baclo fen." Arch Phys Med Rehabil 90(11): 1815 -1820.
Title 21, Code of Federal Regulat ions, Office of the Federal Register, National Archives and 
Records Administration.
U.S. Department of Health and Human Services, FDA, Center for Drug Evaluat ion and Research 
(CDER). Center for Bio logics Evaluat ion and Research (CBER). Guidance for Industry . E6 
Good Clinical Pract ice: Consolidated Guidance. ICH, April 1996, Rockville, Maryland.
Appendix A.  Schedule of Study Procedures
Mallinckrodt Pharmaceuticals, Inc. Protocol CNS -GAB101US
Gablofen®(baclofen injection) Intrathecal Version:  2.0
18December 2014 40 CONFIDENTIALAppendix A : Schedule of Study Procedures: Screening through Single -Dosing Period
Study Procedure Screening BaselineaVisit Scheduleb
Based on 6 -Month Refillc
Study DayDay
-14to -1Day
-3 to 16-Month 9-Month 12-Month 18-Month 24-Month 30-Month 36-Month
Signed informed consent X
Medical history X
Compete physical exam X
Targeted physical exam* X X X X X X X X
Vital signsdX X X X X X X X X
WeightdX X X X X X X X X
Concomitant medication assessment X X X X X
Adverse event assessment X X X X X X X
Gabolfen®3 mg/mL administration Xe
Clinical evaluation for I nflammatory GranulomasfX X X X X X X X
*        A targeted physical exam is defined as a limited examination for the cause and severity of a reported adverse event to assess the need for medical intervention.  A general examination is not necessary.  
a. Baseline evalua tions must be performed with in 72 hours prior to Gablofen 3 mg/mL administration on Day 1 .   Baseline and Screening visit may be combined.   SOC assessments performed prior to informed consent may be 
incorporated from the medical history into study data ,if not performed exclusively f or this clinical trial.
b. All study visits are ±7 days from scheduled date.
c. For subjects that require refills more frequently than every 6 -months due to the daily dose of baclofen, a customized Appendix A schedule may be requested from the Medical Monitor.
d. For vital signs and weight, a best effort should be conducted to obtain these data.  If obtaining these data is not possible due to subject cooperation, the effort should be documented and results recorded as “not evaluable ” 
(NE).
e. Administration of Gablofe n 3 mg/mL will start on Day 1 of the study.
f. If there are clinical signs of an inflammatory granuloma as defined in Section 3.3,the Medical Monitor should be notified and an MRI scheduled to confirm the pathology of the granuloma.
Mallinckrodt Pharmaceuticals , Inc. Protocol CNS -GAB101US
Gablofen (baclofen injection) Version:  2.0
18December 2014 41 CONFIDENTIALAppendix B.  National Cancer Institute
Common Term inology Criteria for Adverse Events
Version 4.03
Publication Date: 14 June 2010
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_8.5x11.pdf